A phase III study of GSK 961081/fluticasone furoate to explore its potential as a once-daily medicine delivered in the ELLIPTA inhaler

Trial Profile

A phase III study of GSK 961081/fluticasone furoate to explore its potential as a once-daily medicine delivered in the ELLIPTA inhaler

Planning
Phase of Trial: Phase III

Latest Information Update: 06 May 2013

At a glance

  • Drugs Batefenterol/fluticasone furoate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top